vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是世纪互联的1.0倍（$373.9M vs $362.7M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs -10.7%，领先18.0%），PHIBRO ANIMAL HEALTH CORP自由现金流更多（$8.3M vs $-193.1M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 17.4%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
PAHC vs VNET — 直观对比
营收规模更大
PAHC
是对方的1.0倍
$362.7M
净利率更高
PAHC
高出18.0%
-10.7%
自由现金流更多
PAHC
多$201.3M
$-193.1M
两年增速更快
PAHC
近两年复合增速
17.4%
损益表 — Q2 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $362.7M |
| 净利润 | $27.5M | $-38.7M |
| 毛利率 | 35.5% | 20.9% |
| 营业利润率 | 13.5% | 0.5% |
| 净利率 | 7.3% | -10.7% |
| 营收同比 | 20.9% | — |
| 净利润同比 | 762.1% | — |
| 每股收益（稀释后） | $0.67 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCVNET
| Q4 25 | $373.9M | — | ||
| Q3 25 | $363.9M | $362.7M | ||
| Q2 25 | $378.7M | — | ||
| Q1 25 | $347.8M | $309.5M | ||
| Q4 24 | $309.3M | — | ||
| Q3 24 | $260.4M | $302.2M | ||
| Q2 24 | $273.2M | $274.4M | ||
| Q1 24 | $263.2M | $262.9M |
净利润PAHCVNET
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.5M | $-38.7M | ||
| Q2 25 | $17.2M | — | ||
| Q1 25 | $20.9M | $-2.4M | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $7.0M | $-2.1M | ||
| Q2 24 | $752.0K | $-1.1M | ||
| Q1 24 | $8.4M | $-22.0M |
毛利率PAHCVNET
| Q4 25 | 35.5% | — | ||
| Q3 25 | 32.9% | 20.9% | ||
| Q2 25 | 29.0% | — | ||
| Q1 25 | 30.1% | 25.2% | ||
| Q4 24 | 32.9% | — | ||
| Q3 24 | 32.1% | 23.2% | ||
| Q2 24 | 31.9% | 21.3% | ||
| Q1 24 | 30.2% | 21.6% |
营业利润率PAHCVNET
| Q4 25 | 13.5% | — | ||
| Q3 25 | 14.1% | 0.5% | ||
| Q2 25 | 8.9% | — | ||
| Q1 25 | 9.6% | 0.1% | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | 6.8% | 24.5% | ||
| Q2 24 | 6.7% | 0.2% | ||
| Q1 24 | 7.6% | 0.2% |
净利率PAHCVNET
| Q4 25 | 7.3% | — | ||
| Q3 25 | 7.3% | -10.7% | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 6.0% | -0.8% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 2.7% | -0.7% | ||
| Q2 24 | 0.3% | -0.4% | ||
| Q1 24 | 3.2% | -8.4% |
每股收益（稀释后）PAHCVNET
| Q4 25 | $0.67 | — | ||
| Q3 25 | $0.65 | — | ||
| Q2 25 | $0.43 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.17 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $492.1M |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $890.8M |
| 总资产 | $1.4B | $6.1B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCVNET
| Q4 25 | $74.5M | — | ||
| Q3 25 | $85.3M | $492.1M | ||
| Q2 25 | $77.0M | — | ||
| Q1 25 | $70.4M | $544.3M | ||
| Q4 24 | $67.1M | — | ||
| Q3 24 | $89.8M | $219.5M | ||
| Q2 24 | $114.6M | $247.2M | ||
| Q1 24 | $98.7M | $246.9M |
总债务PAHCVNET
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | $1.2B | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
股东权益PAHCVNET
| Q4 25 | $332.4M | — | ||
| Q3 25 | $311.7M | $890.8M | ||
| Q2 25 | $285.7M | — | ||
| Q1 25 | $266.0M | $927.8M | ||
| Q4 24 | $246.8M | — | ||
| Q3 24 | $258.5M | $902.9M | ||
| Q2 24 | $256.6M | $900.6M | ||
| Q1 24 | $270.1M | $895.1M |
总资产PAHCVNET
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $6.1B | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | $5.4B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $966.3M | $4.3B | ||
| Q2 24 | $982.2M | $4.0B | ||
| Q1 24 | $979.0M | $3.9B |
负债/权益比PAHCVNET
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | 1.28× | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | $-193.1M |
| 自由现金流率自由现金流/营收 | 2.2% | -53.2% |
| 资本支出强度资本支出/营收 | 3.0% | 84.6% |
| 现金转化率经营现金流/净利润 | 0.70× | — |
| 过去12个月自由现金流最近4个季度 | $47.3M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流PAHCVNET
| Q4 25 | $19.4M | — | ||
| Q3 25 | $9.3M | $113.8M | ||
| Q2 25 | $21.3M | — | ||
| Q1 25 | $43.2M | $27.0M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $12.6M | $108.3M | ||
| Q2 24 | $28.4M | $55.8M | ||
| Q1 24 | $11.4M | $37.1M |
自由现金流PAHCVNET
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | $-193.1M | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | $-220.0M | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | $-95.0M | ||
| Q2 24 | $15.4M | $-81.6M | ||
| Q1 24 | $1.7M | $-102.2M |
自由现金流率PAHCVNET
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | -53.2% | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | -71.1% | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | -31.4% | ||
| Q2 24 | 5.6% | -29.8% | ||
| Q1 24 | 0.6% | -38.9% |
资本支出强度PAHCVNET
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | 84.6% | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | 79.8% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | 67.3% | ||
| Q2 24 | 4.8% | 50.1% | ||
| Q1 24 | 3.7% | 53.0% |
现金转化率PAHCVNET
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 37.80× | — | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
VNET
暂无分部数据
